Serological Cancer Markers

1. Front Matter

   Pages i-xv

   PDF

2. Cancer Markers of the 1990s

   • Stewart Sell

   Pages 1-17

3. Clinical Cancer Markers

   • Manfred L. Lüthgens, Peter Oehr

   Pages 19-29

4. Alpha-Fetoprotein in the 1990s

   • Kazuhisa Taketa

   Pages 31-46

5. Carcinoembryonic Antigen

   • Hanna M. Sikorska, Abraham Fuks, Phil Gold

   Pages 47-97

6. Prostate-Specific Antigen

   • T. Ming Chu

   Pages 99-115

7. Enzyme Markers

   • Doris Balinsky

   Pages 117-133

8. Alkaline Phosphatases as Tumor Markers

   • Torgny Stigbrand, Britta Wahren

   Pages 135-149

9. Sex-Associated Hormones

   • Shahla Masood

   Pages 151-192

10. Tissue Polypeptide Antigen and Specific TPA

    • Peter Oehr, Manfred L. Lüthgens, Qian Liu

    Pages 193-206

11. Tumor-Associated Carbohydrate Markers

    • Sen-itiroh Hakomori

    Pages 207-232

12. Glycoamines: Structural-Functional Characterization of a New Class of Human Tumor Markers

    • Gennadi V. Glinsky

    Pages 233-260

13. CA 15–3 Assay for the Detection of Episialin

    • John Hilkens

    Pages 261-280

14. Clinical Applications of CA 15–3

    • Daniel F. Hayes, Carlo Tondini, Donald W. Kufe

    Pages 281-307

15. CA 19–9, GICA (Gastrointestinal Cancer Antigen)

    • Rolf Lamerz

    Pages 309-339

16. Mucin-Like Cancer-Associated Antigen (MCA) as Available Circulating Tumor Marker for Breast Cancer

    • Emilio Bombardieri, Massimo Gion

    Pages 341-354

17. DU-PAN-2, A Clinically Useful Mucin Marker of Differentiation of Pancreatic and Other Ductal Cells and Their Tumors

    • Richard S. Metzgar, Norio Sawabu, Michael A. Hollingsworth

    Pages 355-374

18. CA 50

    • Caj Haglund, Pentti Kuusela, Peter J. Roberts, Hannu Jalanko

    Pages 375-386

19. TAG-72 as a Tumor Marker

    • Jeffrey Schlom, David Colcher, Diane E. Milenic, Patricia Horan Hand, John W. Greiner, Masahide Kuroki et al.

    Pages 387-416

20. CA 125

    • Fredrick J. Montz

    Pages 417-427

The purpose of this book-the fourth volume of a series on Can­ cer Markers-is intended to provide an updated "status report" on today's use of cancer markers in the diagnosis and monitoring of can­ cer, with an emphasis on cancer markers detected in the serum. It has been 7 years since the publication of the last volume in this series. The 1980, 1982, and 1985 volumes covered the development of cancer markers, not only in their roles of unraveling the basic biology of can­ cer, but also as increasingly important players in the management of patients with cancer. During the last 7 years we have seen the applica­ tion of a number of markers identified by monoclonal antibodies, as well as the beginnings of the use of genetic markers defined by mo­ lecular probes. Measurements of oncogenes in tissues or cells prom­ ise many applications for the future, but as yet, these genes have not shown to be useful as serum markers of cancer. The commercial interest in serum markers for cancer, particu­ larly for the diagnosis and monitoring of tumor patients, is indicated in Chapter 24 by Owen, where the total worldwide market for cancer markers is projected to increase from $148 million in 1988 to $232 million in 1993. The degree of research interest in cancer markers is reflected in the fact that in 1988 a separate category for tumor mark­ ers was added to Index Medicus.

• antigen
• breast cancer
• cancer
• carcinoma
• cell
• embryo
• gastrointestinal cancer
• hormones
• leukemia
• lymphoma
• oncology
• tissue
• tumor

• Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, USA

  Stewart Sell

Policies and ethics